Device Trends To Watch In 2012

For much of the device industry, 2011 was marked by continuing change across the medtech ecosystem, most notably in the economy, the regulatory process, and the financing/innovation model. For 2012, we predict more of the same: the only certainty is continuing uncertainty.

Songwriter Tom Petty observed that “The waiting is the hardest part.” For those who have lived through the past few years in the medical device industry, Petty is truly preaching to the choir. The theme of last year’s annual review of the device industry was change; medtech was in a state of transition, almost as if waiting for the other shoe to drop, on a number of fronts. We optimistically suggested that 2011 would see one or more of those shoes finally fall, bringing some resolution, most notably in the regulatory area. (See Also see "Top Device Stories Of 2010: Waiting For The Other Shoes To Fall" - In Vivo, 1 January, 2011..) However, one year later, about the only thing we can comfortably predict is that the medical device industry is going to be living with uncertainty for the foreseeable future.

Perhaps the best example is the economy. While there is some reason for optimism concerning the state of the US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Luna Health Raises $23.6M, Furthering Launch Of ‘World’s Smallest’ Insulin Pump

 

Luna Health has raised $23.6m in Series A funding to support regulatory submissions, clinical studies and manufacturing for its insulin patch pump.

Industry Experts Expect AI-Driven Medtech M&A To Continue In 2025

 
• By 

AI-driven medtech M&A slowed slightly in volume but tripled in value in early 2025, with buyers focusing on AI-driven diagnostics, surgical tech and analytics. Industry experts expect continued high-value deals as firms defend market share and pursue workflow-enhancing AI.

Apreo Health Raises $130M, First Patient Treated In US Clinical Trial

 

Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.

Exact Sciences Reveals Thinking On CRC Liquid Biopsy After Freenome Deal

 

Exact Sciences has entered into an exclusive licensing agreement with Freenome, stipulating clinical benchmarks and a first-line rating in the USPSTF guidelines. Medtech Insight interviewed screening CMO Paul Limburg about CRC screening and Exact’s strategy on liquid biopsy.

More from Business

Industry Experts Expect AI-Driven Medtech M&A To Continue In 2025

 
• By 

AI-driven medtech M&A slowed slightly in volume but tripled in value in early 2025, with buyers focusing on AI-driven diagnostics, surgical tech and analytics. Industry experts expect continued high-value deals as firms defend market share and pursue workflow-enhancing AI.

Philips Announces Major Investment In US Manufacturing And Expansion Of Pennsylvania Facility

 

Philips says the expansion of its facility in Reedsville, PA, will not only boost its capacity to produce AI-enabled ultrasounds that are used in hospitals across the US but will also create 120 well-paying jobs.

UK’s Dementia Trials Accelerator Works To Fast-Track Recruitment

 

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.